News
Ipsen and Biomunex Pharmaceuticals announced an exclusive global licensing agreement for BMX 502.
Ipsen and Biomunex Pharmaceuticals announced an exclusive global licensing agreement for BMX 502. BMX 502 is a bispecific antibody that engages and activates a subset of cytotoxic T cells called Mucosal-Associated Invariant T cells (MAIT cells) and targets the GPC3 tumor antigen, to kill cancer cells
- GPC3 is a clinically validated target, highly expressed across several cancer types. MAIT cells are present throughout the body, highly enriched in many specific tissues of the body, particularly in mucosal and barrier tissues. BMX 502 offers a promising approach to treating tumors in these tissues.
- Developed using Biomunex’s proprietary BiXAb technology, BMX 502 selectively engages MAIT cells and leverages their unique properties to maximize anti-tumor activity. MAIT engagers should overcome some of the limitations of current pan-T cell engager therapies, including activation of regulatory T cells and cytokine release syndrome, side effects that are difficult to manage for patients and represent a significant burden on the healthcare system. MAIT engagers have the potential to provide a more robust therapeutic window compared to classical pan-T cell engagers in specific tumor types.
- This agreement with such an innovative oncology company as Ipsen is proof of the relevance of MAIT-engager approach of Biomunex, the first company worldwide to have identified the high therapeutic potential of MAIT cells in cancer treatment. It also represents the demonstration of the added-value of our best-in-class BiXAb platform to rapidly generate innovative and promising bispecific antibodies. We are convinced that our MAIT engagers will represent a new step forward in the development of disruptive immuno-therapies for the treatment of cancer. We look forward to initiating and supporting the development of BMX 502 alongside Ipsen,” added Dr. Pierre-Emmanuel Gerard, founder, President and CEO of Biomunex.
- Biomunex has created and developed BiXAb, a robust, “Plug and Play”, next-generation bi- and multi-specific antibody technology platform, using a proprietary computational modeling approach, with a very robust IP and patent portfolio. The BiXAb platform allows the generation ) of bispecific antibodies from any pair of monoclonal antibodies in a simple, fast and cost-effective manner.Biomunex is the first company worldwide developing MAIT engagers, an immuno-oncology approach that allows, through bispecific antibodies from its BiXAb platform, to specifically target and engage MAIT cells, to kill cancer cells, for the treatment of solid tumor.
- Under the terms of the agreement, Biomunex will complete the IND-enabling package. Ipsen will assume responsibility for Phase I preparation activities, including submission of the Investigational New Drug (IND) application, and all subsequent clinical-development and global commercialization activities. Biomunex is eligible to receive up to $610 million, including upfront, contingent upon successful development, regulatory and commercial milestones, in addition to tiered global royalties on sales.rue du Faubourg Saint Jacques, 75014, Paris (FR
Condition: Solid Tumours
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.